Lincoln Pharmaceuticals (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Lincoln Pharmaceuticals Limited |
|||
|
Price: ₹802.30 | ||
| 52 Week Low: ₹534.80 52 Week High: ₹979.50 |
|||
| Market Capital: 1,237.63 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Lincoln Pharmaceuticals Share Price Target For 2024
- 1.1.1: Lincoln Pharmaceuticals Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Lincoln Pharmaceuticals Share Price Target For 2025
- 1.2.1: Lincoln Pharmaceuticals Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Lincoln Pharmaceuticals Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Lincoln Pharmaceuticals Brief Company Overview
- 4: Lincoln Pharmaceuticals Financial Performance
- 4.0.1: Is Lincoln Pharmaceuticals A Good Buy For Long Term?
To predict the Lincoln Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Lincoln Pharmaceuticals Share Price Target For 2024
The line chart displays the monthly closing prices of Lincoln Pharmaceuticals with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Lincoln Pharmaceuticals shares in 2024, see the table below.
Lincoln Pharmaceuticals Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 910.0 (+13.42%) | Price Action: 12 Dec 2024 Low |
| 2024 Target 2 | 895.65 (+11.63%) | Price Action: 19 Dec 2024 High |
| 2024 Target 1 | 885.0 (+10.3%) | Price Action: 05 Dec 2024 Low |
| Current Price | 802.30 | Lincoln Pharmaceuticals's share price as of 23 Dec 2024 |
| Stop Loss 1 | 774.0 (-3.53%) | Price Action: 04 Dec 2024 Low |
| Stop Loss 2 | 763.2 (-4.88%) | Price Action: 03 Dec 2024 High |
| Stop Loss 3 | 753.38 (-6.1%) | Price Action: Feb 2024 High |
Short-Term Technical Outlook
Current Technical Position: Lincoln Pharmaceuticals is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹783.73 serves as the nearest technical reference point.
Historical Returns: 3-month: +21.46% | 6-month: +32.81% | 1-year: +33.54%
Lincoln Pharmaceuticals Share Price Target For 2025
The line chart displays the monthly closing prices of Lincoln Pharmaceuticals with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Lincoln Pharmaceuticals shares in 2025, see the table below.
Lincoln Pharmaceuticals Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1116.41 (+39.15%) | Price Action: Chart |
| 2025 Target 2 | 1095.59 (+36.54%) | Price Action: Chart |
| 2025 Target 1 | 1084.74 (+35.2%) | Fibonacci Extension Level 123.60% |
| Current Price | 802.30 | Lincoln Pharmaceuticals's share price as of 23 Dec 2024 |
| Stop Loss 1 | 727.24 (-9.36%) | Price Action: Aug 2024 High |
| Stop Loss 2 | 713.28 (-11.1%) | Price Action: Jan 2024 High |
| Stop Loss 3 | 703.3 (-12.34%) | Price Action: Dec 2023 High |
Long-Term Technical Outlook
52-Week Range Analysis: Lincoln Pharmaceuticals is currently trading at 60.2% of its 52-week range (₹534.8 - ₹979.5).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +33.54% | 3-year: +129.02% | 5-year: +305.36%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Lincoln Pharmaceuticals Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹802.30 | ||
| 2024 | ₹666.18 | -16.96% | ₹676.17 |
| 2025 | ₹723.88 | +8.66% | ₹737.16 |
| 2026 | ₹783.40 | +8.22% | ₹811.53 |
| 2027 | ₹870.98 | +11.17% | ₹885.89 |
| 2028 | ₹867.36 | -0.41% | ₹880.37 |
| 2029 | ₹944.34 | +8.87% | ₹960.26 |
| 2030 | ₹1,002.85 | +6.19% | ₹1,017.89 |
| 2031 | ₹1,063.70 | +6.06% | ₹1,079.66 |
| 2032 | ₹1,161.80 | +9.22% | ₹1,183.35 |
| 2033 | ₹1,138.84 | -1.97% | ₹1,163.41 |
| 2034 | ₹1,222.51 | +7.34% | ₹1,257.71 |
| 2035 | ₹1,281.81 | +4.85% | ₹1,332.08 |
| 2036 | ₹1,344.00 | +4.85% | ₹1,406.44 |
| 2037 | ₹1,452.62 | +8.08% | ₹1,480.81 |
| 2038 | ₹1,410.32 | -2.91% | ₹1,448.68 |
| 2039 | ₹1,484.76 | +5.27% | ₹1,555.17 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Lincoln Pharmaceuticals Brief Company Overview
Lincoln Pharmaceuticals Limited: A Renowned Pharmaceutical Manufacturer Lincoln Pharmaceuticals Limited, established in 1979, is a leading pharmaceutical manufacturer based in India. The company has a strong global presence, providing a wide range of pharmaceutical...
products in various therapeutic areas. Diverse Product Portfolio: Lincoln Pharmaceuticals boasts a comprehensive product range, including cough and cold medications, ophthalmic products, anti-malarial drugs, vitamins and minerals, anti-bacterial, anti-viral, and anti-fungal medications, analgesics, anti-psychotics, cardiovascular drugs, gastrointestinal products, and dermatological preparations. It also offers branded generics. Commitment to Quality: Lincoln Pharmaceuticals is committed to providing high-quality pharmaceutical products. The company has a strong focus on research and development, ensuring its products meet the highest industry standards. Reputation and Innovation: Over the years, Lincoln Pharmaceuticals has established a strong reputation in the pharmaceutical industry. The company is known for its innovation, quality standards, and commitment to patient health. It continues to explore new therapeutic areas and develop innovative products.Lincoln Pharmaceuticals Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 1,237.63 Crore | Market valuation of Lincoln Pharmaceuticals's shares. |
| Revenue (TTM) | 592.21 Crore | Total revenue generated by Lincoln Pharmaceuticals over the past twelve months. |
| Net Income (TTM) | +97.96 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +13.24% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +16.54% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+8.6% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+24.5% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
0.18 | Company's total debt divided by total shareholder equity. |
| Total Debt | 1.06 Crore | Sum of Lincoln Pharmaceuticals's current & long-term financial obligations. |
| Total Cash | 152.74 Crore | Total amount of liquid funds available to Lincoln Pharmaceuticals. |
| Beta | 0.67 | Beta is less than 1 indicating that the Lincoln Pharmaceuticals's price is less volatile than the market. |
Is Lincoln Pharmaceuticals A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
